Skip to main content
OpenTrials

Clinical trial condition

Lung Neoplasms

Explore clinical trials studying Lung Neoplasms. Study availability and eligibility vary by location and protocol.

4,205 public trials 1,002 recruiting studies
Refine in advanced search Browse all conditions

Lung Neoplasms trial results

Active, Not Recruiting

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

NCT05224141

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases, +7 more
Locations
  • Infirmary Cancer Care ( Site 0022) Mobile, Alabama, United States
  • Los Angeles Hematology Oncology Medical Group ( Site 0006) Los Angeles, California, United States
  • VA West Los Angeles Medical Center ( Site 0004) Los Angeles, California, United States
  • Boca Raton Regional Hospital-Lynn Cancer Institute ( Site 0014) Boca Raton, Florida, United States
View all 140 locations
View Trial Details
Active, Not Recruiting

CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

NCT04062708

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • NorthWestern University Chicago, Illinois, United States
  • University of Chicago Medical Center Chicago, Illinois, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Brigham and Women's Hospital Boston, Massachusetts, United States
View Trial Details
Active, Not Recruiting

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

NCT04721015

Conditions
Advanced Solid Tumors Cancer, Bronchial Neoplasms, Carcinoma, Bronchogenic, +9 more
Locations
  • Dana-Farber Cancer Institute /ID# 231209 Boston, Massachusetts, United States
  • Washington University-School of Medicine /ID# 225698 St Louis, Missouri, United States
  • Carolina BioOncology Institute /ID# 225358 Huntersville, North Carolina, United States
  • Lifespan Cancer Institute at Rhode Island Hospital /ID# 226145 Providence, Rhode Island, United States
View all 33 locations
View Trial Details
Active, Not Recruiting

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

NCT05607550

Conditions
Advanced Non-Small Cell Lung Cancer, Bronchial Neoplasms, Carcinoma, Bronchogenic, +10 more
Locations
  • Arrivent Investigative Site Daphne, Alabama, United States
  • Arrivent Investigative Site Yuma, Arizona, United States
  • Arrivent Investigative Site Fayetteville, Arkansas, United States
  • Arrivent Investigative Site Beverly Hills, California, United States
View all 208 locations
View Trial Details
Active, Not Recruiting

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

NCT04676477

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +12 more
Locations
  • UCLA Santa Monica, California, United States
  • Yale University School of Medicine - Yale-New Haven Hospital New Haven, Connecticut, United States
  • Georgetown University Medical Center Washington D.C., District of Columbia, United States
  • Northwestern University Feinberg School of Medicine Chicago, Illinois, United States
View all 31 locations
View Trial Details

Related conditions